 |
第59巻第7号目次 | Japanese/English |
 | Full Text of PDF (415K) Article in Japanese |
─ 原著 ─
The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy
Yukie Omori1, Sotaro Enatsu1, Alan J.M. Brnabic2, Narayan Rajan2, Jin-Yuan Shih3, Joo-Hang Kim4, Keunchil Park5, Akira Inoue61Eli Lilly Japan K.K., Japan, 2Eli Lilly Australia Pty Ltd, Australia, 3National Taiwan University Hospital, Taiwan, 4CHA Bundang Medical Center, Republic of Korea, 5Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea, 6Tohoku University, Japan
Objectives. The relevance of febrile neutropenia (FN) to patient-reported outcomes (PROs) was examined in Japanese, East Asian (EA), and non-EA patients with stage IV non-small cell lung cancer. Materials and Methods. PROs were assessed with the Lung Cancer Symptom Scale (LCSS) and EuroQoL-5 Dimensions (EQ-5D) at baseline, every cycle, at discontinuation, and at 30-day follow-up. The time to deterioration (TtD) and mean changes (baseline to treatment completion) in the LCSS total score, average symptom burden index (ASBI), and EQ-5D visual analog scale (VAS) scores were analyzed by the FN status, regardless of the assigned treatment. Results. For patients with and without FN, the hazard ratios (HRs; 95％ confidence interval [CI]) for TtD of the LCSS total, ASBI, and EQ-5D VAS scores were 0.731 (0.469-1.141), 0.621 (0.399-0.967), and 0.802 (0.537-1.199) in Japanese patients, and 0.572 (0.250-1.313), 0.506 (0.228-1.121), and 0.792 (0.350-1.790) in EA patients, respectively, indicating a longer TtD in PROs for patients without FN than for those with FN, while no marked differences by the FN status were noted in non-EA patients. Across the three populations, the mean change in both the LCSS total and EQ-5D VAS scores demonstrated a greater deterioration at treatment completion for patients with FN than for those without FN. Conclusions. PROs deteriorated more rapidly in patients with FN than in those without FN among Japanese and EA patients but not non-EA patients. Upon treatment completion, PROs were better maintained in patients without FN than in those with FN in all three populations. These findings suggest that active prevention of FN may help maintain PROs during treatment, regardless of ethnic group (ClinicalTrials.gov registration: NCT01703091 and NCT01168973).
索引用語：Docetaxel, Febrile neutropenia, Non-small cell lung cancer, Patient-reported outcome, Quality of life
受付日：April 18, 2019
受理日：September 21, 2019
肺癌 59 (7)：1140─1150，2019
